undamentalytics Newsletter
Sign in

Scilex Holding Co (SCLX) stock

Add to watchlist

Add holding +

NASDAQ: SCLX Nasdaq Pharmaceuticals

D Fundamentals grade

Scilex Holding Co is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Scilex Holding Co is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Scilex Holding Co valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
  • Funds21 adding, 17 cuttingOf 6 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Scilex Holding files

Where Scilex stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $32m, down 28.5% on a year earlier, a smaller fall than the 33.2% decline a quarter earlier. Free-cash-flow margin fell to -70.7% from 42.3% a year earlier. Operating margin narrowed to -1136.4% from -218.6%. It passes 0 of our 3 financial-health checks.

Our model value for Scilex Holding is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Scilex Holding Co's trailing-twelve-month revenue fell 28.5% year on year, with a free-cash-flow margin of -70.7%. Where it stands out: change in growth rate of +4.7pp ranks 13 of 74 pharmaceuticals companies we cover. Where it lags: net margin of -1469.8% ranks 71 of 75 pharmaceuticals companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 203% year over year while revenue fell 29% — the balance sheet is expanding 231 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Scilex Holding Co's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 28.5% over the last 12 months.
  • Loss-making. Operating margin is -1136.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 917.8 points on a year ago.
  • Burning cash. Free cash flow was -70.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 51.0% of revenue, against a median of 3.6% for pharmaceuticals companies we cover: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 100% and a beta of 0.8 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$1.17 against an average estimate of -$0.47: missed by 149.3%
Revenue
$8m, down 22.8% on a year earlier

Scilex Holding's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.1%
  • 1 week-19.7%
  • 1 month-53.9%
  • This year-75.4%
  • 1 year-81.8%
  • 5 years-99.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$31.6M
Operating margin
-1136.4%
Net margin
-1469.8%

Growth

Revenue growth
−28.5%
Change in growth rate
+4.7 pts

Cash

Free cash flow (TTM)
-$22.3M
FCF margin
-70.7%
Stock pay % of revenue
51.0%

Earnings

Last results
October 8, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement
  3. Deal
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Scilex Holding Co valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Scilex Holding Co as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.07 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$4.7–$20 Left out: out of range vs price (0.01x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Scilex Holding Co with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$218.80$86.96$44.46$9.28$7.60
Market value$58m$23m$11.5bn$94185$84m
+ Net debt (− = net cash)$106m−$2m$122m$32m$101m
Enterprise value$163m$21m$11.6bn$33m$185m
Multiples
Price / sales 1.8x0.6xn/m0.0x2.8x
Price / earnings —————
Price / free cash flow ———0.0x22.8x
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Scilex Holding Co: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2025 −$0.47 −$1.17 −149.3%
Sept 2025 −$0.41 −$21.29 −5093.4%
Jun 2025 −$0.91 −$7.42 −715.4%
Mar 2025 −$0.01 −$1.73 −17202.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
2.7%
of tradable shares
Days to cover
3.43
at average volume
Short interest, 1 month
−16%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
11.7%
of shares
Employees
34
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
SCLX−60%−49%−79%−18%−75%
Industry peers (median)−49%−13%−2%+9%−12%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
SCLX67%33%33%58%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
SCLX−73%−94%−84%−78%−81%
S&P 500−25%−10%−8%−19%−9%

Worst fall since March 5, 2021: 99% from April 12, 2023 to October 30, 2026. Getting back needed a 17335% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.85 – $14.02
From 52-week high
−86.7%
vs 50-day average
−54.3%
vs 200-day average
−64.6%
Volatility (1 year)
100%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.1%
After a week
3 up, 9 down
typical move ±14.7%
After a month
5 up, 7 down
typical move ±23.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 8, 2024 −10.7% +1.6% −11.8% +16.8%
August 1, 2024 −9.4% −3.3% −17.0% −27.7%
July 1, 2024 0.0% +0.9% −6.7% −17.6%
April 16, 2024 −8.6% −0.8% −23.7% −36.1%
March 5, 2024 +1.5% −0.5% −1.5% +14.2%
January 2, 2024 −2.9% −1.4% +5.9% −21.1%
December 1, 2023 +4.0% +0.1% −12.0% +58.4%
November 1, 2023 −1.1% +3.0% −28.9% −27.8%
October 2, 2023 −10.0% −1.4% +30.0% +33.6%
September 11, 2023 −3.9% +0.1% −22.0% −18.1%
July 5, 2023 +1.2% −0.9% −5.4% +10.9%
June 1, 2023 +7.7% +2.4% +11.6% −4.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Scilex Holding Co in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Scilex Holding Co
$30M $40M $50M $60M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $45.2M Revenue (TTM), FY23 Q4: $46.7M Revenue (TTM), FY24 Q1: $47M Revenue (TTM), FY24 Q2: $50.8M Revenue (TTM), FY24 Q3: $55.2M Revenue (TTM), FY24 Q4: $56.6M Revenue (TTM), FY25 Q1: $50.7M Revenue (TTM), FY25 Q2: $44.2M Revenue (TTM), FY25 Q3: $40.4M Revenue (TTM), FY25 Q4: $30.3M Revenue (TTM), FY26 Q1: $33.9M Revenue (TTM), FY26 Q2: $31.6M $31.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $45.2M
FY23 Q4 $46.7M
FY24 Q1 $47M
FY24 Q2 $50.8M
FY24 Q3 $55.2M
FY24 Q4 $56.6M
FY25 Q1 $50.7M
FY25 Q2 $44.2M
FY25 Q3 $40.4M
FY25 Q4 $30.3M
FY26 Q1 $33.9M
FY26 Q2 $31.6M
Revenue growth, TTM YoY Scilex Holding Co
-60% -40% -20% 0% 20% 40% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q4: 22.9% Revenue growth, TTM YoY, FY24 Q1: 12.5% Revenue growth, TTM YoY, FY24 Q2: 9.4% Revenue growth, TTM YoY, FY24 Q3: 22.0% Revenue growth, TTM YoY, FY24 Q4: 21.1% Revenue growth, TTM YoY, FY25 Q1: 7.8% Revenue growth, TTM YoY, FY25 Q2: -13.0% Revenue growth, TTM YoY, FY25 Q3: -26.8% Revenue growth, TTM YoY, FY25 Q4: -46.5% Revenue growth, TTM YoY, FY26 Q1: -33.2% Revenue growth, TTM YoY, FY26 Q2: -28.5% -28.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 22.9%
FY24 Q1 12.5%
FY24 Q2 9.4%
FY24 Q3 22.0%
FY24 Q4 21.1%
FY25 Q1 7.8%
FY25 Q2 -13.0%
FY25 Q3 -26.8%
FY25 Q4 -46.5%
FY26 Q1 -33.2%
FY26 Q2 -28.5%
Operating margin (TTM) Scilex Holding Co
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -236.4% Operating margin (TTM), FY23 Q4: -225.6% Operating margin (TTM), FY24 Q1: -211.4% Operating margin (TTM), FY24 Q2: -181.5% Operating margin (TTM), FY24 Q3: -133.0% Operating margin (TTM), FY24 Q4: -147.4% Operating margin (TTM), FY25 Q1: -181.1% Operating margin (TTM), FY25 Q2: -218.6% Operating margin (TTM), FY25 Q3: -652.4% Operating margin (TTM), FY25 Q4: -1143.7% Operating margin (TTM), FY26 Q1: -1034.4% Operating margin (TTM), FY26 Q2: -1136.4% -1136.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -236.4%
FY23 Q4 -225.6%
FY24 Q1 -211.4%
FY24 Q2 -181.5%
FY24 Q3 -133.0%
FY24 Q4 -147.4%
FY25 Q1 -181.1%
FY25 Q2 -218.6%
FY25 Q3 -652.4%
FY25 Q4 -1143.7%
FY26 Q1 -1034.4%
FY26 Q2 -1136.4%
FCF margin (TTM) Scilex Holding Co
-100% -50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -40.1% FCF margin (TTM), FY23 Q4: -48.8% FCF margin (TTM), FY24 Q1: -12.0% FCF margin (TTM), FY24 Q2: 19.9% FCF margin (TTM), FY24 Q3: 17.0% FCF margin (TTM), FY24 Q4: 30.6% FCF margin (TTM), FY25 Q1: 27.5% FCF margin (TTM), FY25 Q2: 42.3% FCF margin (TTM), FY25 Q3: 54.0% FCF margin (TTM), FY25 Q4: 4.0% FCF margin (TTM), FY26 Q1: -22.9% FCF margin (TTM), FY26 Q2: -70.7% -70.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -40.1%
FY23 Q4 -48.8%
FY24 Q1 -12.0%
FY24 Q2 19.9%
FY24 Q3 17.0%
FY24 Q4 30.6%
FY25 Q1 27.5%
FY25 Q2 42.3%
FY25 Q3 54.0%
FY25 Q4 4.0%
FY26 Q1 -22.9%
FY26 Q2 -70.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 24 31 38 47 57 30 32
Gross profit 21 28 27 31 167 126 18
EBITDA −31 −32 −47 −101 −79 −341 −354
Operating income −35 −36 −51 −105 −83 −346 −359
Net income −48 −88 −23 −114 −73 −374 −465
Diluted EPS −$2.54 −$338.34 −$85.85 −$646.38 −$8.05 −$36.48 —
Growth (year on year)
Revenue — +32.9% +21.4% +22.9% +21.1% −46.5% −28.5%
Margins
Gross margin 90.9% 88.4% 71.6% 66.5% — — 55.5%
EBITDA margin −133.6% −102.4% −122.7% −216.7% −140.2% <−999% <−999%
Operating margin −149.7% −114.4% −133.1% −225.6% −147.4% <−999% <−999%
Net margin −201.7% −282.4% −61.4% −244.6% −128.7% <−999% <−999%
Free-cash-flow margin −133.6% −91.5% −55.9% −44.4% 34.2% 12.2% —
Cash flow
Cash from operations −31 −29 −21 −21 19 4 −17
Capital spending 0 0 0 0 0 0 —
Free cash flow −31 −29 −21 −21 19 4 —
Stock-based pay 5 6 5 15 16 15 16
Free cash flow after stock pay −37 −34 −27 −35 4 −12 —
Balance sheet
Cash 0 4 2 4 3 5 1
Total debt 0 110 0 125 36 106 81
Net debt (negative = net cash) −0 106 −2 122 32 101 80
Diluted shares 19m — — 258m — 11m —
Returned to shareholders
Dividends — — — 9 9 — —
Total returned — — — 9 9 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 3 checks passed · June 30, 2026
What it owns · $254m
Short-term assets $36mLonger-term assets $217m
What it owes, and who funded it · $564m
Short-term liabilities $512mLonger-term liabilities $52mShareholders' equity $-308m
  • Short-term assets cover short-term liabilities $36m of assets due within a year against $512m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $36m short-term assets against $52m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$359m against $16m of interest.

From Scilex Holding Co's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
58.9%
of revenue
Sales & admin spending
879.4%
of revenue
Days sales outstanding
74 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SCLX VRCA SBFM JAGX BGM IMCC Median
Revenue, last 12 months $32m $30m $35m $28m $38m $39m $276m
Revenue growth, last 12 months −28.5% 106.2% −2.7% 135.5% 51.1% −0.7% 9.9%
Revenue growth, 3-year average −12.0% 52.2% 34.5% 76.5% — — 5.5%
Revenue growth, latest quarter −22.8% −53.8% −1.6% −58.9% — — 6.5%
Gross margin 55.5% 63.8% 30.3% 82.3% 16.6% 17.7% 62.0%
Operating margin <−999% −93.6% −16.6% −93.1% −33.2% −21.2% −5.9%
Operating margin, 3-year average −512.2% −312.8% −16.5% −227.7% — — −7.4%
Net margin <−999% −102.8% −16.5% −188.5% −52.6% −20.7% −7.3%
Cash from operations / revenue −54.1% −44.0% −15.1% −24.0% −6.3% 8.6% 10.2%
Free-cash-flow margin −70.7% −44.0% −15.2% −24.0% −10.4% 8.6% 8.6%
Free-cash-flow margin, 3-year average −2.8% −280.0% −25.5% −182.5% — — 7.4%
Stock pay / revenue 51.0% 11.6% — 2.1% 27.0% 0.0% 3.6%
Change in share count — 5.6% 55.7% — >999% 71.3% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -28.5% 10.0% 67 of 74
Change in growth rate Growth +4.7pp -0.3pp 13 of 74
Gross margin Profitability 55.5% 59.8% 33 of 59
Operating margin Profitability -1136.4% -5.9% 62 of 67
Net margin Profitability -1469.8% -7.3% 71 of 75
Free-cash-flow margin Cash generation -70.7% 10.1% 64 of 74
Stock pay as % of revenue Cash generation 51.0% 3.6% 64 of 69
Days sales outstanding Balance sheet 74 days 72 days 32 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$5.5M
Institutions reporting
70
Shares held vs prior quarter
▼ 19.4%
Positions opened / closed
9 / 10

Top buyers and sellers, Q2 2026: 21 institutions bought and 17 sold ; the biggest buyer was Jacobs Levy Equity Management, Inc (+41K shares) and the biggest seller Armistice Capital, LLC (−298K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $2.4M 301K 42.9% ▲ 14.1%
Blackrock, Inc. $853,453 109K 15.6% ▲ 6.4%
Vanguard Fiduciary Trust Co $357,412 46K 6.5% ▲ 15.5%
Jacobs Levy Equity Management, Inc $321,071 41K 5.9% New
State Street Corp $275,933 35K 5.0% 0.0%
UBS Group AG $260,333 33K 4.7% ▲ 416.0%
Renaissance Technologies LLC $257,899 33K 4.7% ▼ 10.3%
Citadel Advisors LLC $214,477 27K 3.9% New
Price T Rowe Associates Inc $164,000 21K 3.0% New
Ashton Thomas Private Wealth, LLC $144,160 18K 2.6% ▲ 2.7%
Northern Trust Corp $117,367 15K 2.1% ▲ 0.1%
Morgan Stanley $31,454 4K 0.6% ▼ 66.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Scilex Holding Co's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $57.8M 13 trades by 1 insider · 0% under pre-set plans
Net ▼ $57.8M net selling
Insider Date Trade Shares Price Value
Scilex Holding Co 10% owner January 14, 2026 Sell 5,115,586 $0.72 $3.7M
Scilex Holding Co 10% owner January 13, 2026 Sell 175,139 $0.91 $159,674
Scilex Holding Co 10% owner January 12, 2026 Sell 10,674,816 $0.88 $9.4M
Scilex Holding Co 10% owner January 8, 2026 Sell 3,824,201 $1.07 $4.1M
Scilex Holding Co 10% owner January 7, 2026 Sell 4,835,581 $1.20 $5.8M
Scilex Holding Co 10% owner January 6, 2026 Sell 6,053,708 $1.37 $8.3M
Scilex Holding Co 10% owner December 30, 2025 Sell 9,657,300 $0.54 $5.2M
Scilex Holding Co 10% owner December 30, 2025 Sell 9,657,300 $0.54 $5.2M
Scilex Holding Co 10% owner December 29, 2025 Sell 7,310,984 $0.66 $4.8M
Scilex Holding Co 10% owner December 29, 2025 Sell 7,310,984 $0.66 $4.8M
Scilex Holding Co 10% owner December 26, 2025 Sell 3,689,016 $0.75 $2.8M
Scilex Holding Co 10% owner December 26, 2025 Sell 3,689,016 $0.75 $2.8M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 8, 2024
  • August 1, 2024
  • July 1, 2024
  • April 16, 2024
  • March 5, 2024
  • January 2, 2024

Recent SEC filings

Data status

When each part of this page on Scilex Holding Co was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Scilex Holding Co in brief

What does Scilex Holding Co do?
Scilex Holding Co is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Scilex Holding Co's stock ticker?
Scilex Holding Co trades under the ticker SCLX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Scilex Holding Co's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Scilex Holding Co reported revenue of $31.6M, 28.5% lower than a year earlier, according to its SEC filings.
What is Scilex Holding Co's free cash flow?
Scilex Holding Co's free-cash-flow margin is -70.7% of revenue over the trailing twelve months, ranking 64 of the 74 pharmaceuticals companies we cover.
Who are Scilex Holding Co's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Blackrock, Inc. and Vanguard Fiduciary Trust Co. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Scilex Holding Co's market cap?
On December 31, 2025, Scilex Holding Co's market capitalisation was about $83.8M and net debt of $101M. Market figures come from third-party market data and may be delayed.
Who are Scilex Holding Co's competitors?
In our Pharmaceuticals peer group, the companies closest to Scilex Holding Co are Verrica Pharmaceuticals Inc., Sunshine Biopharma Inc., Jaguar Health, Inc., BGM Group Ltd. and IM Cannabis Corp. The side-by-side comparison below sets their revenue, margins and growth against Scilex Holding Co's.
Are insiders buying or selling Scilex Holding Co stock?
Over the last 12 months, Scilex Holding Co's directors and officers reported 0 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.